These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35750559)

  • 1. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.
    Pohar KS; Patel S; Lotan Y; Trabulsi E; Woods M; Downs T; Huang WC; Jones J; Taylor J; O'Donnell M; Bivalacqua TJ; DeCastro J; Steinberg G; Kamat AM; Resnick MJ; Konety B; Schoenberg M; Jones JS; Daneshmand S;
    Urol Oncol; 2022 Aug; 40(8):382.e1-382.e6. PubMed ID: 35750559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
    Renninger M; Fahmy O; Schubert T; Schmid MA; Hassan F; Stenzl A; Gakis G
    World J Urol; 2020 Feb; 38(2):397-406. PubMed ID: 31030231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.
    Witjes JA; Gomella LG; Stenzl A; Chang SS; Zaak D; Grossman HB
    Urology; 2014 Jul; 84(1):122-6. PubMed ID: 24768013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
    Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
    J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
    Lotan Y; Bivalacqua TJ; Downs T; Huang W; Jones J; Kamat AM; Konety B; Malmström PU; McKiernan J; O'Donnell M; Patel S; Pohar K; Resnick M; Sankin A; Smith A; Steinberg G; Trabulsi E; Woods M; Daneshmand S
    Nat Rev Urol; 2019 Jun; 16(6):377-386. PubMed ID: 31019310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
    Bader MJ; Stepp H; Beyer W; Pongratz T; Sroka R; Kriegmair M; Zaak D; Welschof M; Tilki D; Stief CG; Waidelich R
    Urol Oncol; 2013 Oct; 31(7):1178-83. PubMed ID: 22440147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blue Light Cystoscopy: Indications and Outcomes.
    Pohar KS
    Curr Urol Rep; 2020 Apr; 21(5):19. PubMed ID: 32248340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.
    Gkritsios P; Hatzimouratidis K; Kazantzidis S; Dimitriadis G; Ioannidis E; Katsikas V
    Int Urol Nephrol; 2014 May; 46(5):927-33. PubMed ID: 24249423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
    Zhao H; Peng P; Luo Z; Liu H; Sun J; Wang X; Jia Q; Yang Z
    Photodiagnosis Photodyn Ther; 2023 Mar; 41():103220. PubMed ID: 36462704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
    Dansk V; Malmström PU; Bläckberg M; Malmenäs M
    Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
    Geavlete B; Jecu M; Multescu R; Georgescu D; Geavlete P
    Urology; 2010 Sep; 76(3):664-9. PubMed ID: 20627289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
    Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
    Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
    Loidl W; Schmidbauer J; Susani M; Marberger M
    Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.